Aerovate Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2022 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aerovate Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q3 2024.
  • Aerovate Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 16.4 %, a 70.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 16.4 +6.8 +70.7% Sep 30, 2024
Q2 2024 15.8 +7.67 +94.7% Jun 30, 2024
Q1 2024 13.4 +7.2 +116% Mar 31, 2024
Q4 2023 11.9 +7.26 +157% Dec 31, 2023
Q3 2023 9.62 +6.24 +184% Sep 30, 2023
Q2 2023 8.1 +5.56 +219% Jun 30, 2023
Q1 2023 6.23 Mar 31, 2023
Q4 2022 4.62 Dec 31, 2022
Q3 2022 3.39 Sep 30, 2022
Q2 2022 2.54 Jun 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.